Results for 'Drug industry'

997 found
Order:
  1.  34
    Strategic Corporate Social Responsibility and Orphan Drug Development: Insights From the US and the EU Biopharmaceutical Industry[REVIEW]Olga Bruyaka, Hanko K. Zeitzmann, Isabelle Chalamon, Richard E. Wokutch & Pooja Thakur - 2013 - Journal of Business Ethics 117 (1):45-65.
    In recent years, the biopharmaceutical industry has seen an increase in the development of so-called orphan drugs for the treatment of rare and neglected diseases. This increase has been spurred on by legislation in the United States, Europe, and elsewhere designed to promote orphan drug development. In this article, we examine the drivers of corporate social responsibility (CSR) activities in orphan drug markets and the extent to which biopharmaceutical firms engage in these activities with a strategic orientation. (...)
    Direct download (3 more)  
     
    Export citation  
     
    Bookmark   2 citations  
  2.  22
    Bad Medicine. The Prescription Drug Industry in the Third World. M. Silverman, M. Lydecker, Ph. R. Lee. Stanford, California: Stanford University Press, 1992, ISBN 0-8047-1669-. [REVIEW]Klaus M. Leisinger - 1993 - Cambridge Quarterly of Healthcare Ethics 2 (3):388.
    Direct download (6 more)  
     
    Export citation  
     
    Bookmark  
  3.  12
    Review of Sonia Shah. The Body Hunters: How the Drug Industry Tests its Products on the World's Poorest Patients. [REVIEW]Jennifer S. Bard - 2008 - American Journal of Bioethics 8 (2):52 – 53.
    Direct download (2 more)  
     
    Export citation  
     
    Bookmark  
  4.  9
    Myths and Misconceptions About Drug Industry Ethics.Bert Spilker - 1984 - International Journal of Applied Philosophy 2 (2):1-11.
    Direct download (4 more)  
     
    Export citation  
     
    Bookmark  
  5.  2
    Taking Money From the Drug Industry: The Rules Tighten.Carl Elliott - 2003 - Hastings Center Report 33 (4):6-7.
    Direct download  
     
    Export citation  
     
    Bookmark  
  6.  4
    Generic Drug Competition: The Pharmaceutical Industry “Gaming” Controversy.Thomas A. Hemphill - 2019 - Business and Society Review 124 (4):467-477.
    No categories
    Direct download (3 more)  
     
    Export citation  
     
    Bookmark  
  7. Integrating Research and Development: The Emergence of Rational Drug Design in the Pharmaceutical Industry.Matthias Adam - 2005 - Studies in History and Philosophy of Science Part C: Studies in History and Philosophy of Biological and Biomedical Sciences 36 (3):513-537.
    Rational drug design is a method for developing new pharmaceuticals that typically involves the elucidation of fundamental physiological mechanisms. It thus combines the quest for a scientific understanding of natural phenomena with the design of useful technology and hence integrates epistemic and practical aims of research and development. Case studies of the rational design of the cardiovascular drugs propranolol, captopril and losartan provide insights into characteristics and conditions of this integration. Rational drug design became possible in the 1950s (...)
    Direct download (7 more)  
     
    Export citation  
     
    Bookmark   7 citations  
  8.  8
    Integrating Research and Development: The Emergence of Rational Drug Design in the Pharmaceutical Industry.Matthias Adam - 2005 - Studies in History and Philosophy of Science Part C: Studies in History and Philosophy of Biological and Biomedical Sciences 36 (3):513-537.
    Rational drug design is a method for developing new pharmaceuticals that typically involves the elucidation of fundamental physiological mechanisms. It thus combines the quest for a scientific understanding of natural phenomena with the design of useful technology and hence integrates epistemic and practical aims of research and development. Case studies of the rational design of the cardiovascular drugs propranolol, captopril and losartan provide insights into characteristics and conditions of this integration. Rational drug design became possible in the 1950s (...)
    Direct download (5 more)  
     
    Export citation  
     
    Bookmark   6 citations  
  9.  16
    Recent Efforts to Elucidate the Scientific Validity of Animal-Based Drug Tests by the Pharmaceutical Industry, Pro-Testing Lobby Groups, and Animal Welfare Organisations.Jarrod Bailey & Michael Balls - 2019 - BMC Medical Ethics 20 (1):16.
    Even after several decades of human drug development, there remains an absence of published, substantial, comprehensive data to validate the use of animals in preclinical drug testing, and to point to their pr...
    Direct download (4 more)  
     
    Export citation  
     
    Bookmark  
  10.  18
    Book Reviews : Abraham J 1995: Science, Politics and the Pharmaceutical Industry; Controversy and Bias in Drug Regulation. London: UCL Press . 308pp. £12.95 . ISBN 1 85728 200 0. [REVIEW]C. Agathangelou - 1996 - Nursing Ethics 3 (2):181-182.
  11.  20
    Drug Familiarization and Therapeutic Misconception Via Direct-to-Consumer Information.Jean-Christophe Bélisle-Pipon & Bryn Williams-Jones - 2015 - Journal of Bioethical Inquiry 12 (2):259-267.
    Promotion of prescription drugs may appear to be severely limited in some jurisdictions due to restrictions on direct-to-consumer advertising. However, in most jurisdictions, strategies exist to raise consumer awareness about prescription drugs, notably through the deployment of direct-to-consumer information campaigns that encourage patients to seek help for particular medical conditions. In Canada, DTCI is presented by industry and regulated by Health Canada as being purely informational activities, but their design and integration in broader promotional campaigns raise very similar ethical (...)
    Direct download (2 more)  
     
    Export citation  
     
    Bookmark   1 citation  
  12.  17
    Shortcomings of Protocols of Drug Trials in Relation to Sponsorship as Identified by Research Ethics Committees: Analysis of Comments Raised During Ethical Review.Marlies van Lent, Gerard A. Rongen & Henk J. Out - 2014 - BMC Medical Ethics 15 (1):83.
    Submission of study protocols to research ethics committees constitutes one of the earliest stages at which planned trials are documented in detail. Previous studies have investigated the amendments requested from researchers by RECs, but the type of issues raised during REC review have not been compared by sponsor type. The objective of this study was to identify recurring shortcomings in protocols of drug trials based on REC comments and to assess whether these were more common among industry-sponsored or (...)
    Direct download (8 more)  
     
    Export citation  
     
    Bookmark   1 citation  
  13.  45
    Banning All Drug Promotion is the Best Option Pending Major Reforms.Peter R. Mansfield - 2005 - Journal of Bioethical Inquiry 2 (2):75-81.
    Drug promotion should be evaluated according to its impact on health, access to information, informed consent, and wealth. Drug promotion currently does more harm than good to each of these objectives because it is usually misleading. This is a systemic problem. Whilst improved regulation and education will address it to some degree, major reforms to payment systems for drug companies and doctors are also required. Until all these systemic reforms can be put in place, the best policy (...)
    Direct download (3 more)  
     
    Export citation  
     
    Bookmark   4 citations  
  14.  28
    Understanding Physician-Pharmaceutical Industry Interactions.Shaili Jain - 2007 - Cambridge University Press.
    Physician-pharmaceutical industry interactions continue to generate heated debate in academic and public domains, both in the United States and abroad. Despite this, recent research suggests that physicians and physicians-in-training remain ignorant of the core issues and are ill-prepared to understand pharmaceutical industry promotion. There is a vast medical literature on this topic, but no single, concise resource. This book aims to fill that gap by providing a resource that explains the essential elements of this subject. The text makes (...)
    Direct download  
     
    Export citation  
     
    Bookmark  
  15.  9
    Managing Relationships with Industry: A Physician's Compliance Manual.Steven C. Schachter (ed.) - 2008 - Elsevier.
    Background -- Overview of legal sources -- Summary of recent prosecutions and investigations -- Applications of law and professional and trade association standards to physician relationships with industry -- Legal and ethical aspects of specific physician's industry financial relationships -- Approaching and adopting effective compliance plans.
    Direct download  
     
    Export citation  
     
    Bookmark  
  16.  8
    How IRB Leaders View and Approach Challenges Raised by Industry-Funded Research.R. Klitzman - 2013 - IRB: Ethics & Human Research 35 (3):9-17.
  17.  20
    Drugs, Money, and Power: The Canadian Drug Shortage.Chris Kaposy - 2014 - Journal of Bioethical Inquiry 11 (1):85-89.
    This article describes the shortage of generic injectable medications in Canada that affected hospitals in 2012. It traces the events leading up to the drug shortage, the causes of the shortage, and the responses by health administrators, pharmacists, and ethicists. The article argues that generic drug shortages are an ethical problem because health care organizations and governments have an obligation to avoid exposing patients to resource scarcity. The article also discusses some options governments could pursue in order to (...)
    Direct download (2 more)  
     
    Export citation  
     
    Bookmark   1 citation  
  18.  31
    Ethical Issues in New Drug Prescribing.Lindsay W. Cole, Jennifer C. Kesselheim & Aaron S. Kesselheim - 2012 - Journal of Bioethical Inquiry 9 (1):77-83.
    We use the format of a hypothetical case study to review issues related to pharmaceutical product approval and physician prescribing practices. In this case, a new FDA-approved drug is recommended for a patient who subsequently experiences an adverse event that may or may not be related to the prescription. This case raises a number of ethical and legal considerations physicians routinely face when deciding whether to recommend such drugs for their patients. Despite the need for ongoing observation by the (...)
    Direct download (3 more)  
     
    Export citation  
     
    Bookmark  
  19.  11
    Institutional Mistrust in the Organization of Pharmaceutical Clinical Trials.Jill A. Fisher - 2008 - Medicine, Health Care and Philosophy 11 (4):403-413.
    In this paper I explore the politics of trust in the clinical testing of pharmaceuticals in the US. Specifically, I analyze trust in terms of its institutional manifestations in the pharmaceutical clinical trials industry. In the process of testing new drugs, pharmaceutical companies must (1) protect their proprietary information from the clinicians who conduct their studies, and (2) find a way to ensure human subjects’ compliance to study protocols. Concern with these two critical issues leads drug companies to (...)
    Direct download (5 more)  
     
    Export citation  
     
    Bookmark   3 citations  
  20.  14
    An Update to Returning Genetic Research Results to Individuals: Perspectives of the Industry Pharmacogenomics Working Group.Sandra K. Prucka, Lester J. Arnold, John E. Brandt, Sandra Gilardi, Lea C. Harty, Feng Hong, Joanne Malia & David J. Pulford - 2015 - Bioethics 29 (2):82-90.
    The ease with which genotyping technologies generate tremendous amounts of data on research participants has been well chronicled, a feat that continues to become both faster and cheaper to perform. In parallel to these advances come additional ethical considerations and debates, one of which centers on providing individual research results and incidental findings back to research participants taking part in genetic research efforts. In 2006 the Industry Pharmacogenomics Working Group offered some ‘Points-to-Consider’ on this topic within the context of (...)
    Direct download (7 more)  
     
    Export citation  
     
    Bookmark   2 citations  
  21.  73
    Extraordinary Pricing of Orphan Drugs: Is It a Socially Responsible Strategy for the U.S. Pharmaceutical Industry[REVIEW]Thomas A. Hemphill - 2010 - Journal of Business Ethics 94 (2):225 - 242.
    The PRIME Institute of the College of Pharmacy, University of Minnesota, recently released preliminary research findings indicating a trend of extraordinary pharmaceutical industry pricing of drug products in the United States (U.S.). According to researchers at the PRIME Institute, such extraordinary price increases are defined as any price increase that is equal to, or greater than, 100% at a single point in time. In some instances, PRIME Institute researchers found that drugs exhibiting extraordinary price increases are categorized as (...)
    Direct download (4 more)  
     
    Export citation  
     
    Bookmark   3 citations  
  22.  30
    Feeling Is Believing: Evaluative Conditioning and the Ethics of Pharmaceutical Advertising.Paul Biegler & Patrick Vargas - 2016 - Journal of Bioethical Inquiry 13 (2):271-279.
    A central goal in regulating direct-to-consumer advertising of prescription pharmaceuticals is to ensure that explicit drug claims are truthful. Yet imagery can also alter viewer attitudes, and the degree to which this occurs in DTCA is uncertain. Addressing this data gap, we provide evidence that positive feelings produced by images can promote favourable beliefs about pharmaceuticals. We had participants view a fictitious anti-influenza drug paired with unrelated images that elicited either positive, neutral or negative feelings. Participants who viewed (...)
    Direct download (2 more)  
     
    Export citation  
     
    Bookmark   1 citation  
  23.  38
    The Law and Ethics of the Pharmaceutical Industry.M. N. G. Dukes - 2005 - Elsevier.
    As one of the most massive and successful business sectors, the pharmaceutical industry is a potent force for good in the community, yet its behaviour is frequently questioned: could it serve society at large better than it has done in the recent past? Its own internal ethics, both in business and science, may need a careful reappraisal, as may the extent to which the law - administrative, civil and criminal - succeeds in guiding (and where neccessary contraining) it. The (...)
    Direct download  
     
    Export citation  
     
    Bookmark   2 citations  
  24.  49
    Conflicts of Interest in Drug Development: The Practices of Merck & Co., Inc.Laurence J. Hirsch - 2002 - Science and Engineering Ethics 8 (3):429-442.
    Conflicts of interest are common and exist in academia, government, and many industries, including pharmaceutical development. Medical journal editors and others have recently criticized “the pharmaceutical industry,” citing concerns over investigator access to data, approaches to analysis of clinical trial data, and publication practices. Merck & Co., Inc. is a global, research-driven pharmaceutical company that discovers, develops, manufactures, and markets a broad range of human and animal health products, directly and through its joint ventures. Although part of its mission (...)
    Direct download (3 more)  
     
    Export citation  
     
    Bookmark   1 citation  
  25.  23
    Corpus Interruptus: Biotech Drugs, Insurance Providers and the Treatment of Breast Cancer. [REVIEW]Jane E. Schultz - 2007 - Journal of Bioethical Inquiry 4 (2):103-103.
    In researching the biomedically-engineered drug Neulasta (filgrastim), a breast cancer patient becomes aware of the extent to which knowledge about the development and marketing of drugs influences her decisions with regard to treatment. Time spent on understanding the commercial interests of insurers and pharmaceutical companies initially thwarts but ultimately aids the healing process. This first-person narrative calls for physicians to recognize that the alignment of commercial interests transgresses the patient’s humanity.
    Direct download (5 more)  
     
    Export citation  
     
    Bookmark   1 citation  
  26.  77
    Bioethics, Vulnerability, and Protection.Ruth Macklin - 2003 - Bioethics 17 (5-6):472--486.
    What makes individuals, groups, or even entire countries vulnerable? And why is vulnerability a concern in bioethics? A simple answer to both questions is that vulnerable individuals and groups are subject to exploitation, and exploitation is morally wrong. This analysis is limited to two areas. First is the context of multinational research, in which vulnerable people can be exploited even if they are not harmed, and harmed even if they are not exploited. Second is the situation of women, who are (...)
    Direct download (5 more)  
     
    Export citation  
     
    Bookmark   39 citations  
  27.  72
    The Research Subject as Wage Earner.James A. Anderson & Charles Weijer - 2002 - Theoretical Medicine and Bioethics 23 (4-5):359-376.
    The practice of paying research subjects for participating inclinical trials has yet to receive an adequate moral analysis.Dickert and Grady argue for a wage payment model in whichresearch subjects are paid an hourly wage based on that ofunskilled laborers. If we accept this approach, what follows?Norms for just working conditions emerge from workplacelegislation and political theory. All workers, includingpaid research subjects under Dickert and Grady''s analysis,have a right to at least minimum wage, a standard work week,extra pay for overtime hours, (...)
    Direct download (5 more)  
     
    Export citation  
     
    Bookmark   16 citations  
  28. What is Personalized Medicine: Sharpening a Vague Term Based on a Systematic Literature Review.Sebastian Schleidgen & Georg Marckmann - 2013 - BMC Medical Ethics 14 (1):20.
    In recent years, personalized medicine (PM) has become a highly regarded line of development in medicine. Yet, it is still a relatively new field. As a consequence, the discussion of its future developments, in particular of its ethical implications, in most cases can only be anticipative. Such anticipative discussions, however, pose several challenges. Nevertheless, they play a crucial role for shaping PM’s further developments. Therefore, it is vital to understand how the ethical discourse on PM is conducted, i.e. on what (...)
    Direct download (15 more)  
     
    Export citation  
     
    Bookmark   4 citations  
  29.  77
    Is Banning Direct to Consumer Advertising of Prescription Medicine Justified Paternalism?Uvonne Lau - 2005 - Journal of Bioethical Inquiry 2 (2):69-74.
    New Zealand is one of two OECD countries in the world where direct-to-consumer advertising of prescription medicine (DTCA-PM) is permitted. Increase in such activity in recent years has resulted in a disproportionate increase in dispensary volume of heavily advertised medicines. Concern for the potential harm to healthcare consumers and the public healthcare system has prompted the medical profession to call for a ban on DTCA-PM as the best way of protecting the public interest. Such blanket prohibition however also interferes with (...)
    Direct download (4 more)  
     
    Export citation  
     
    Bookmark   3 citations  
  30. Adventure! Comedy! Tragedy! Robots! How Bioethicists Learned to Stop Worrying and Embrace Their Inner Cyborgs.Carl Elliott - 2005 - Journal of Bioethical Inquiry 2 (1):18-23.
  31.  12
    Researchers and Subpoenas: The Troubling Precedent of the Selikoff Case.A. R. Holder - 1988 - IRB: Ethics & Human Research 11 (6):8-10.
    Direct download  
     
    Export citation  
     
    Bookmark  
  32.  6
    Community Pharmacy Dispensing of Prescription Medicine Sample Packs: Changing the Business of Medicine Initiation?Greg J. Kyle, Lisa Nissen & Susan Tett - 2010 - Journal of Evaluation in Clinical Practice 16 (6):1357-1360.
  33.  29
    Drug Advertising, Continuing Medical Education, and Physician Prescribing: A Historical Review and Reform Proposal.Marc A. Rodwin - 2010 - Journal of Law, Medicine and Ethics 38 (4):807-815.
    Through the 1960s, many people claimed that drug advertising was educational and physicians often relied on it. Continuing Medical Education (CME) was developed to provide an alternative. However, because CME relied on grants, industry funders chose the subjects offered. Now policymakers worry that drug firms support CME to promote sales and that commercial support biases prescribing and fosters inappropriate drug use. A historical review reveals parallel problems between advertising and industry-funded CME. To preclude industry (...)
    Direct download (5 more)  
     
    Export citation  
     
    Bookmark   10 citations  
  34.  28
    Drug Firms, the Codification of Diagnostic Categories, and Bias in Clinical Guidelines.Lisa Cosgrove & Emily E. Wheeler - 2013 - Journal of Law, Medicine and Ethics 41 (3):644-653.
    The possibility that industry is exerting an undue influence on the culture of medicine has profound implications for the profession's public health mission. Policy analysts, investigative journalists, researchers, and clinicians have questioned whether academic-industry relationships have had a corrupting effect on evidence-based medicine. Psychiatry has been at the heart of this epistemic and ethical crisis in medicine. This article examines how commercial entities, such as pharmaceutical companies, influence psychiatric taxonomy and treatment guidelines. Using the conceptual framework of institutional (...)
    Direct download (5 more)  
     
    Export citation  
     
    Bookmark   6 citations  
  35.  47
    All Gifts Large and Small: Toward an Understanding of the Ethics of Pharmaceutical Industry Gift-Giving.Jon F. Merz, Arthur L. Caplan & Dana Katz - 2010 - American Journal of Bioethics 10 (10):11-17.
    Much attention has been focused in recent years on the ethical acceptability of physicians receiving gifts from drug companies. Professional guidelines recognize industry gifts as a conflict of interest and establish thresholds prohibiting the exchange of large gifts while expressly allowing for the exchange of small gifts such as pens, note pads, and coffee. Considerable evidence from the social sciences suggests that gifts of negligible value can influence the behavior of the recipient in ways the recipient does not (...)
    Direct download (3 more)  
     
    Export citation  
     
    Bookmark   6 citations  
  36.  6
    Interactions of Doctors with the Pharmaceutical Industry.M. A. Morgan - 2006 - Journal of Medical Ethics 32 (10):559-563.
    Objective: To assess the opinions and practice patterns of obstetrician-gynaecologists on acceptance and use of free drug samples and other incentive items from pharmaceutical representatives.Methods: A questionnaire was mailed in March 2003 to 397 members of the American College of Obstetricians and Gynecologists who participate in the Collaborative Ambulatory Research Network.Results: The response rate was 55%. Most respondents thought it proper to accept drug samples , an informational lunch , an anatomical model or a well-paid consultantship from pharmaceutical (...)
    Direct download (6 more)  
     
    Export citation  
     
    Bookmark   7 citations  
  37.  16
    Reforming Pharmaceutical Industry-Physician Financial Relationships: Lessons From the United States, France, and Japan.Marc A. Rodwin - 2011 - Journal of Law, Medicine and Ethics 39 (4):662-670.
    This article compares the means that the United States, France, and Japan use to oversee pharmaceutical industry-physician financial relationships. These countries rely on professional and/or industry ethical codes, anti-kickback laws, and fair trade practice laws. They restrict kickbacks the most strictly, allow wide latitude on gifts, and generally permit drug firms to fund professional activities and associations. Consequently, to avoid legal liability, drug firms often replace kickbacks with gifts and grants. The paper concludes by proposing reforms (...)
    Direct download (5 more)  
     
    Export citation  
     
    Bookmark   4 citations  
  38.  65
    Ethical Issues in Outsourcing: The Case of Contract Medical Research and the Global Pharmaceutical Industry[REVIEW]Henry Adobor - 2012 - Journal of Business Ethics 105 (2):239-255.
    The outsourcing of medical research has become a strategic imperative in the global pharmaceutical industry. Spurred by the challenges of competition, the need for speed in drug development, and increasing domestic costs, pharmaceutical companies across the globe continue to outsource critical parts of their value chain activities, namely contract clinical research and drug testing, to sponsors across the globe, typically into emerging markets. While it is clear that important ethical issues arise with this practice, unraveling moral responsibility (...)
    Direct download (4 more)  
     
    Export citation  
     
    Bookmark   2 citations  
  39.  51
    Where Strategy and Ethics Converge: Pharmaceutical Industry Pricing Policy for Medicare Part D Beneficiaries.Edward R. Balotsky - 2009 - Journal of Business Ethics 84 (S1):75 - 88.
    On January 1, 2006, Medicare Part D prescription drug coverage was initiated. Concern was immediately voiced by the American Association of Retired Persons (AARP) and Families USA that, in response to this program, the pharmaceutical industry may raise prices for drugs most often used by the elderly. This article examines the ethical implications of a revenue-maximizing pricing strategy in an industry in which third party financing mitigates an end product's true cost to the user. The perspectives of (...)
    Direct download (4 more)  
     
    Export citation  
     
    Bookmark   3 citations  
  40.  1
    Regulation and Paediatric Drug Trials: Patents, Plans, and Perverse Incentives.Riana Gaifulinay - 2011 - Research Ethics 7 (2):51-57.
    The facilitation of tight regulatory frameworks necessary to ensure that new drugs are safe and effective have yet to be effectively applied within the paediatric population. Utilization of unlicensed and off-label drugs in children results in a variety of problems ranging from inefficacy, adverse reactions and in some cases death. This ethically questionable behaviour has led the European government to legally force pharmaceutical companies to propose paediatric applications and carry out clinical studies at early stages of drug development. The (...)
    Direct download (8 more)  
     
    Export citation  
     
    Bookmark   1 citation  
  41.  3
    The Effects of Industry Funding and Positive Outcomes in the Interpretation of Clinical Trial Results: A Randomized Trial Among Dutch Psychiatrists.Joeri K. Tijdink, Yvo M. Smulders, Lex M. Bouter & Christiaan H. Vinkers - 2019 - BMC Medical Ethics 20 (1):1-8.
    Most studies are inclined to report positive rather than negative or inconclusive results. It is currently unknown how clinicians appraise the results of a randomized clinical trial. For example, how does the study funding source influence the appraisal of an RCT, and do positive findings influence perceived credibility and clinical relevance? This study investigates whether psychiatrists’ appraisal of a scientific abstract is influenced by industry funding disclosures and a positive outcome. Dutch psychiatrists were randomized to evaluate a scientific abstract (...)
    No categories
    Direct download (4 more)  
    Translate
     
     
    Export citation  
     
    Bookmark  
  42.  15
    Human Stakeholders and the Use of Animals in Drug Development.Lisa A. Kramer & Ray Greek - 2018 - Business and Society Review 123 (1):3-58.
    Pharmaceutical firms seek to fulfill their responsibilities to stakeholders by developing drugs that treat diseases. We evaluate the social and financial costs of developing new drugs relative to the realized benefits and find the industry falls short of its potential. This is primarily due to legislation-mandated reliance on animal test results in early stages of the drug development process, leading to a mere 10 percent success rate for new drugs entering human clinical trials. We cite hundreds of biomedical (...)
    No categories
    Direct download (7 more)  
     
    Export citation  
     
    Bookmark  
  43.  40
    Do Drug Advertisements Provide Therapeutic Information?G. V. Stimson - 1977 - Journal of Medical Ethics 3 (1):7-13.
    In this study of advertisements appearing in medical periodicals and by direct mail advertising to general practitioners, Dr. Stimson, a sociologist, concludes that from what is intended to provide therapeutic information hardly any therapeutic information is provided. He reminds the reader of the safeguards which surround all drug advertising by law and by the code of practice of the Association of the British Pharmaceutical Industry but these safeguards do not appear to control real or potential sins of omission. (...)
    Direct download (6 more)  
     
    Export citation  
     
    Bookmark  
  44.  20
    Industry, Innovation and Social Values.Dr Harvey E. Bale Jr - 2005 - Science and Engineering Ethics 11 (1):31-40.
    Remaining important tasks in finding and developing new drugs and vaccines for HIV/AIDS, malaria, cancer and other diseases require continued industry research and development. Industry’s research and development pipeline has produced drugs that have saved AIDS victims previously facing certain death, but still no cure nor vaccine is yet available. Experience with the process of research and development indicates that it requires more than a decade of development to produce a new drug with costs in the hundreds (...)
    Direct download (3 more)  
     
    Export citation  
     
    Bookmark  
  45.  29
    Industry, Innovation and Social Values.Harvey E. Bale - 2005 - Science and Engineering Ethics 11 (1):31-40.
    Remaining important tasks in finding and developing new drugs and vaccines for HIV/AIDS, malaria, cancer and other diseases require continued industry research and development. Industry’s research and development pipeline has produced drugs that have saved AIDS victims previously facing certain death, but still no cure nor vaccine is yet available. Experience with the process of research and development indicates that it requires more than a decade of development to produce a new drug with costs in the hundreds (...)
    Direct download (3 more)  
     
    Export citation  
     
    Bookmark  
  46.  3
    Pharmacogenetics and Pharmacogenomics: Public Policy and Bioethical Issues Associated with Patents for Drug Development.Arthur Falek & Michael W. Jann - 2000 - Global Bioethics 13 (3-4):29-42.
    The genetic component of variations in human responses to pharmacological agents is called pharmacogenetics while the molecular basis for these variations are most often identified as pharmacogenomics. Pharmacogenomics as a field of scientific endeavor is so new that in the scientific literature the two terms are often used interchangeably. In fact, the search for new drugs at the molecular level start with the identification of variations in DNA sequences whose products produce alterations in the amino acid structure of the active (...)
    No categories
    Direct download (2 more)  
     
    Export citation  
     
    Bookmark  
  47.  9
    The Ethics of the Pharmaceutical Industry and the Need for a Dual Market System.Anna Kreiner - 1995 - Journal of Medical Humanities 16 (1):55-68.
    In an era of increasing medical costs and cries for health care reform in the United States, the pharmaceutical industry has come under intense scrutiny. Ethical issues are inherent in the pharmaceutical marketplace, and there is a need to address the moral rights and responsibilities of drug manufacturers consumers, health care professionals, and governmental agents in the production, distribution, regulation, and use of these products. A dual market system protecting individual rights to access and autonomy without placing an (...)
    Direct download (3 more)  
     
    Export citation  
     
    Bookmark  
  48.  7
    Better Regulation of Industry-Sponsored Clinical Trials Is Long Overdue.Matthew Wynia & David Boren - 2009 - Journal of Law, Medicine and Ethics 37 (3):410-419.
    Regulating clinical trials for testing new drugs is fraught with risk. Misregulation can slow development of innovative and useful new drugs, but in other ways misregulation can foster trials that are inefficient and unethical, driven by commercial rather than scientific ends, and that can harm patients. In this paper, we argue not for more but for better regulation, based on the goal of rapidly producing innovative and safe products that represent significant advances in medical care. Data on industry-funded, late-stage (...)
    Direct download (3 more)  
     
    Export citation  
     
    Bookmark  
  49.  35
    The Political and Ethical Challenge of Multi-Drug Resistant Tuberculosis.Ross Upshur, Ian Kerridge, Wendy Lipworth, Christopher Mayes & Chris Degeling - 2015 - Journal of Bioethical Inquiry 12 (1):107-113.
    This article critically examines current responses to multi-drug resistant tuberculosis and argues that bioethics needs to be willing to engage in a more radical critique of the problem than is currently offered. In particular, we need to focus not simply on market-driven models of innovation and anti-microbial solutions to emergent and re-emergent infections such as TB. The global community also needs to address poverty and the structural factors that entrench inequalities—thus moving beyond the orthodox medical/public health frame of reference.
    Direct download (5 more)  
     
    Export citation  
     
    Bookmark   1 citation  
  50.  45
    In the Grip of the Python: Conflicts at the University-Industry Interface.David Healy - 2003 - Science and Engineering Ethics 9 (1):59-71.
    When the University of Toronto withdrew a contract it held with me in December 2000, it initiated a sequence of events that led to a public letter to the University from senior figures in the world psychopharmacology community protesting against the infringement of academic freedom involved and a first ever legal action, undertaked by this author, seeking redress for a violation of academic freedom. The issues of academic freedom surrounding this case have been intertwined with a debate about the possibility (...)
    Direct download (3 more)  
     
    Export citation  
     
    Bookmark   4 citations  
1 — 50 / 997